Bodo Brauer, MD
Family Medicine · Port Arthur, TXNPI 1679579908
Payments from drug & device makers
Across 357 payments — averaging $16.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$650
- GSK$570
- Amarin Pharma, Inc.$469
- AstraZeneca$465
- Amgen$420
- Smith+Nephew$368
- plus $3K from 34 others
What the payments were for
- Food & beverage$5,737100%
- Education$50%
- Gifts$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 54 | $650 |
| GSK | 40 | $570 |
| Amarin Pharma, Inc. | 29 | $469 |
| AstraZeneca | 29 | $465 |
| Amgen | 28 | $420 |
| Smith+Nephew | 18 | $368 |
| Novo Nordisk | 27 | $363 |
| Johnson & Johnson | 23 | $346 |
| KCI USA, Inc. | 4 | $208 |
| Kowa Pharmaceuticals America, Inc. | 10 | $158 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $156 |
| Pfizer | 11 | $152 |
| Sanofi-aventis U.S. LLC | 7 | $117 |
| Intuitive Surgical | 1 | $99 |
| Melinta Therapeutics, LLC | 5 | $89 |
| Bayer | 4 | $88 |
| Merck | 5 | $81 |
| Sunovion Pharmaceuticals Inc. | 7 | $77 |
| Regeneron Healthcare Solutions, Inc. | 4 | $75 |
| Regeneron | 1 | $73 |
| SK Life Science, Inc. | 3 | $71 |
| Novartis | 4 | $68 |
| Lilly USA, LLC | 4 | $56 |
| Biogen | 3 | $56 |
| Boehringer Ingelheim | 3 | $54 |
| Aytu Biopharma, Inc. | 3 | $51 |
| Shire North American Group Inc | 3 | $49 |
| Arbor Pharmaceuticals, Inc. | 3 | $40 |
| Ironwood Pharmaceuticals, Inc | 2 | $37 |
| Esperion Therapeutics, Inc. | 2 | $37 |
| Biohaven Pharmaceuticals, Inc. | 2 | $35 |
| Eisai Inc. | 2 | $33 |
| Daiichi Sankyo Inc. | 2 | $30 |
| Abbott | 1 | $25 |
| Aroa Biosurgery Incorporated | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Organogenesis Inc. | 1 | $16 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VAC ULTA$119
- VAC VERAFLO$119
- VAC VERAFLO CLEANSE CHOICE$119
How this compares
$5,757 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 48 | $47,984 |
| OzempicSemaglutide | 29 | $29,505 |
| FarxigaDapagliflozin Propanediol | 40 | $28,429 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $19,755 |
| JardianceEmpagliflozin | 18 | $17,047 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 234 | $5,914 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 88 | $4,237 |
| Esomeprazole Magnesium | 15 | $4,139 |
| Testosterone Cypionate | 44 | $2,737 |
| Rosuvastatin Calcium | 238 | $2,451 |
| Atorvastatin Calcium | 322 | $2,150 |
| Gabapentin | 124 | $1,896 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 62 | $1,632 |
| Metoprolol Succinate | 114 | $1,434 |
| Losartan Potassium | 123 | $1,231 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $152 | $47,98448 claims |
| Novo NordiskOzempic | $363 | $29,50529 claims |
| AstraZenecaFarxiga | $465 | $28,42940 claims |
| GSKTrelegy Ellipta | $570 | $19,75522 claims |
| Boehringer IngelheimJardiance | $54 | $17,04718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Port Arthur
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.